Boston Therapeutics, Inc. Reports First Quarter Results and Provides Corporate Update
20. Mai 2015 16:54 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 20, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate...
Boston Therapeutics Announces Fourth Quarter and Fiscal Year 2014 Financial Results and Provides Corporate Update
27. März 2015 13:14 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Mar 27, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate...
Boston Therapeutics' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial in Hong Kong
25. März 2015 06:36 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Mar 25, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), affiliate in Hong Kong, Advance Pharmaceutical Company, Ltd. (APC), initiated enrollment of the first...
Boston Therapeutics and Advance Pharmaceutical Expand sugardown(R) Licensing Agreement to Japan; Increases Number of Asian Countries to 16
17. März 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Mar 17, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of complex carbohydrates to treat diabetes and inflammatory diseases, and Advance...
Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial
27. Januar 2015 07:33 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Jan 27, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed...
Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks
20. Januar 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Jan 20, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown®...
Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco
07. Januar 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Jan 7, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a...
Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages
06. Januar 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Jan 6, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a...
Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
10. Dezember 2014 08:20 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Dec 10, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced...
Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
21. November 2014 07:40 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Nov 21, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and...